Sunesis Pharmaceuticals, Inc. (SNSS) Provides Update Concerning Phase 2 Clinical Trials for Vosaroxin in AML
Today before the opening bell, Sunesis Pharmaceuticals, Inc. announced positive data from Phase 2 clinical trials of the company's lead drug candidate, vosaroxin, in combination with cytarabine, a widely used chemotherapy, in relapsed/refractory acute myeloid leukemia (AML) and as a single agent in frontline elderly AML. The data were presented today by Robert Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, at the Chemotherapy Foundation Symposium XXVIII in New York City. The presentation is available to the public on the Sunesis website at www.sunesis.com. For the fully enrolled relapsed/refractory AML study, a…